3:34 PM
 | 
Oct 12, 2017
 |  BC Extra  |  Company News

AcelRx's Dsuvia gets CRL

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) sank $3.20 (60%) to $2.15 after FDA issued a complete response letter for its NDA for Dsuvia sufentanil sublingual tablet (ARX-04) to treat moderate-to-severe acute pain in medically supervised settings. The CRL is the second the...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >